Avoiding idiosyncratic DILI: Two is better than one
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Drug-induced liver injury (DILI) can mimic all forms of acute and chronic liver disease but the rare occurrence of acute liver failure particularly has put the onus on industry and regulatory bodies to protect the general public. Consequently, identifying hepatotoxic potential prior to approval and marketing has assumed a critical role. The traditional approach has been to monitor for alanine aminotransferase (ALT) increases in clinical trials. Although this has proven to be effective in identifying a toxic potential, considerable financial investment already has been made in reaching this stage of drug development. Therefore, it would be beneficial in compound selection or for heightened vigilance in developing specific agents to identify which chemical entities are entirely safe and which have potential liability before ever reaching a human subject. Administration of drugs at high doses to several animal species for varying durations, seeking pathologic changes, is a requirement but as often as not fails to identify the risk of liver injury for drugs that reach man. The reasons include differences in metabolic pathways of drug handling and the current lack of suitable animal models that reproduce the human risk factors. Nevertheless, animal testing does successfully identify many highly toxic chemicals that are similar to acetaminophen in directly injuring the liver. ALT, alanine aminotransferase; ATP, adenosine triphosphate; BSEP, bile salt export pump; DILI, drug-induced liver injury; ER, endoplasmic reticulum; GSH, glutathione; HLA, human leukocyte antigen; IDILI, idiosyncratic DILI; MHC, major histocompatibility complex. With the exception of acetaminophen, most drugs that are known to cause DILI in man do so in an unpredictable fashion with a relatively long latency in a small proportion of exposed individuals and this is referred to as idiosyncratic DILI (IDILI), reflecting the unique susceptibility of certain individuals. Recent evidence has strongly implicated adaptive immunity determined by genetic polymorphisms in major histocompatibility complex (MHC) Class I and II genes in the pathogenesis of IDILI.1 These associations have been described with flucloxacillin, ximelagatran, ticoplidine, lumiracoxib, lapatanib, and amoxiclillin-clavulanate. The absence of the specific haplotype strongly predicts that no DILI will occur, whereas the presence of the common genetic variant is a poor predictor, indicating that it is necessary but not sufficient to lead to IDILI. The big question currently facing this field is what else other than human leukocyte antigen (HLA) contributes to the pathogenesis of IDILI and is it related to the drugs' chemistry or how the patient handles the drug, or both. In the current issue, Chen et al.2 provide evidence that the chemical entity itself, particularly with respect to dose and its physiochemical nature (lipophilicity), is a key factor. They assessed the predictive value of dose (≥100 mg per day) and calculated octanol-water partition coefficient (logP > 3) in two independent databases of Food and Drug Administration (FDA)-approved drugs labeled for the presence or absence of liver injury. The present study confirms previous studies that suggested both factors separately could predict hepatotoxicity3-7 and suggests that a "rule-of-two" which combines both dose and lipophilicity performs better than dose alone, increasing the positive predictive value of dose alone from 85% to 96% ("rule-of-two") while decreasing the negative predictive value from 55% to 39%. Whereas only 8 of 114 drugs in the two databases with no DILI concern exhibited positive "rule-of-two," only half of the hepatotoxic drugs were positive. Thus, false-positives were low but false-negatives were substantial. Clearly, the "rule-of-two" is far from perfect and cannot replace preclinical testing but could be useful as an additional guide in compound selection during drug development. One interesting clinical application of the "rule-of-two" was illustrated by performance in six cases of DILI from LiverTox who received multiple medications; in five cases the implicated drug was the only one exhibiting a positive "rule-of-two." This suggests that application of "rule-of-two" or a facsimile may improve causality assessment in the setting of multiple medications. Why should dose and lipophilicity be of predictive value? Likely this is because of the need for the liver to be exposed to a threshold level of the parent drug and/or reactive metabolite. Lipophilic drugs are cleared by the liver and generally require biotransformation to be eliminated. As noted by the authors, a significant relationship was observed between the extent of hepatic metabolism and logP (calculated-water partition coefficient). Therefore, logP may simply be a surrogate for extensive biotransformation and hepatic exposure to a reactive metabolite. Indeed, others have shown the increased predictive value of combining dose with informati
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dawson, S., Stahl, S., Paul, N., Barber, J., & Kenna, J. G. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040758 · Cited by 343
Cited by
EASL Clinical Practice Guidelines: Drug-induced liver injury
Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.02.014 · Cited by 1,276
“Lipophilic drugs generally require hepatic metabolism to be eliminated and LogP may therefore simply be a surrogate for extensive biotransformation and hepatic exposure to reactive metabolites.(125) A more recent analysis of LogP, daily dose and degree of hepatic metabolism across 5 publically available drug datasets…”
BackgroundSelf-citationAndrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Self-citationDrug-induced liver injury: Interactions between drug properties and host factors
Chen, M., Suzuki, A., Borlak, J., Andrade, R. J., & Lucena, M. I. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.016 · Cited by 405
Lipophilic Efficiency as an Important Metric in Drug Design
Johnson, T. W., Gallego, R. A., & Edwards, M. P. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00077 · Cited by 349
Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives
Fontana, R. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.032 · Cited by 313
Metadata
- Authors
- Kaplowitz, N.
- Venue
- Hepatology
- Published
- 2013-07
- Volume
- 58
- Issue
- 1
- Pages
- 15-17
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2059688608
- Cited by
- 51
- References
- 1
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.